Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT04106219
Title A Study of LY3295668 Erbumine in Participants With Relapsed/Refractory Neuroblastoma
Recruitment Recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors Eli Lilly and Company
Indications

neuroblastoma

Therapies

LY3295668

Cyclophosphamide + LY3295668 + Topotecan

Age Groups: child | adult
Covered Countries USA | CAN


No variant requirements are available.